Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
| ▸ | DUT | P33316 | 2/20 | 0.30 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.30 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.30 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.30 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5466523 | 0.88 | KCNH2 (0.39) | KCNH2IRAK4BACE1LMNAHRH4 | |
| SCHEMBL4712759 | 0.87 | HRH1 (0.37) | KCNH2IRAK4BACE1NOS1NOS2 | |
| SCHEMBL20416847 | 0.84 | KCNH2 (0.39) | KCNH2IRAK4BACE1LMNADUT | |
| SCHEMBL20436590 | 0.84 | KCNH2 (0.39) | KCNH2IRAK4BACE1LMNAHRH4 | |
| SCHEMBL29529715 | 0.83 | KCNH2 (0.38) | KCNH2IRAK4BACE1LMNAHRH4 | |
| SCHEMBL29994742 | 0.83 | KCNH2 (0.38) | KCNH2IRAK4BACE1LMNADUT | |
| SCHEMBL3534071 | 0.83 | NOS2 (0.38) | KCNH2IRAK4BACE1NOS1NOS2 | |
| SCHEMBL379113 | 0.83 | KCNH2 (0.38) | KCNH2IRAK4BACE1LMNADUT | |
| SCHEMBL4715736 | 0.83 | KCNH2 (0.38) | KCNH2IRAK4BACE1LMNAHRH4 | |
| SCHEMBL20436593 | 0.81 | TAAR1 (0.33) | KCNH2IRAK4BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2511260-B1 | AROMATIC COMPOUND, MODIFICATION CARRIER THAT USES SAME AND IS USED FOR SYNTHESIZING AN OLIGONUCLEOTIDE DERIVATIVE, OLIGONUCLEOTIDE DERIVATIVE, AND OLIGONUCLEOTIDE CONSTRUCT | UNIV GIFU (JP) | 2015-07-29 | — | — | EP | disclosed |
| US-8633304-B2 | Oligonucleotide derivative comprising an aromatic compound | GIFU UNIVERSITY (JP) | 2014-01-21 | — | — | US | disclosed |
| US-8633304-B2 | Oligonucleotide derivative comprising an aromatic compound | GIFU UNIVERSITY (JP) | 2014-01-21 | — | — | US | disclosed |
| EP-2511260-A1 | AROMATIC COMPOUND, MODIFICATION CARRIER THAT USES SAME AND IS USED FOR SYNTHESIZING AN OLIGONUCLEOTIDE DERIVATIVE, OLIGONUCLEOTIDE DERIVATIVE, AND OLIGONUCLEOTIDE CONSTRUCT | Gifu University (JP) | 2012-10-17 | — | — | EP | disclosed |
| US-20120245341-A1 | AROMATIC COMPOUND, MODIFICATION CARRIER THAT USES SAME AND IS USED FOR SYNTHESIZING AN OLIGONUCLEOTIDE DERIVATIVE, OLIGONUCLEOTIDE DERIVATIVE, AND OLIGONUCLEOTIDE CONSTRUCT | GIFU UNIVERSITY (JP) | 2012-09-27 | — | — | US | disclosed |
| US-20120245341-A1 | AROMATIC COMPOUND, MODIFICATION CARRIER THAT USES SAME AND IS USED FOR SYNTHESIZING AN OLIGONUCLEOTIDE DERIVATIVE, OLIGONUCLEOTIDE DERIVATIVE, AND OLIGONUCLEOTIDE CONSTRUCT | GIFU UNIVERSITY (JP) | 2012-09-27 | — | — | US | disclosed |
| WO-2011071078-A1 | AROMATIC COMPOUND, MODIFICATION CARRIER THAT USES SAME AND IS USED FOR SYNTHESIZING AN OLIGONUCLEOTIDE DERIVATIVE, OLIGONUCLEOTIDE DERIVATIVE, AND OLIGONUCLEOTIDE CONSTRUCT | 国立大学法人岐阜大学 (JP) | 2011-06-16 | — | — | WO | disclosed |
| US-7875600-B2 | Pyrimidine compounds as purine receptor antagonist | VERNALIS (R&D) LIMITED (GB) | 2011-01-25 | — | — | US | disclosed |
| US-20070281936-A1 | To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide | VERNALIS (R & D ) LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| EP-1720553-A1 | PYRIMIDINE COMPOUNDS AS PURINE RECEPTOR ANTAGONIST | VERNALIS (R&D) LTD (GB) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005079801-A1 | PYRIMIDINE COMPOUNDS AS PURINE RECEPTOR ANTAGONIST | VERNALIS (R & D) LTD (GB) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245341-A1 | AROMATIC COMPOUND, MODIFICATION CARRIER THAT USES SAME AND IS USED FOR SYNTHESIZING AN OLIGONUCLEOTIDE DERIVATIVE, OLIGONUCLEOTIDE DERIVATIVE, AND OLIGONUCLEOTIDE CONSTRUCT | NSUN2, SLCO2A1, ABCB7 | KCNH2 1341/4885IRAK4 2514/4885BACE1 3420/4885 |
| US-20070281936-A1 | To reducte the purinergic neurotransmission; Parkinson's disease; dyskinesias; Movement disorders; Adenosine receptors antagonists; 2-Methylamino-6-(5-methyl-2-furyl)-N-(2-pyridylmethyl)pyrimidine-4-carboxamide | ADORA2A, ADORA3, ADORA1 | KCNH2 645/4885IRAK4 4160/4885BACE1 2013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.